Tumour-derived substrate-adherent cells promote neuroblastoma survival through secreted trophic factors

Mol Oncol. 2021 Aug;15(8):2011-2025. doi: 10.1002/1878-0261.12969. Epub 2021 May 6.

Abstract

Neuroblastoma (NB) is the most common extracranial solid tumour in children. NB is highly heterogeneous and is comprised of a mixture of neuroblastic cancer cells and stromal cells. We previously reported that N-type cells (neuroblastic cells) and S-type cells (substrate-adherent cells) in the SK-N-SH cell line shared almost identical genetic backgrounds. Sublines of N- and S-type cells were isolated from an early passage (P35) of SK-N-SH. Sequencing analysis revealed that all sublines harboured the anaplastic lymphoma kinase (ALK) F1174L mutation, indicating that they were tumour derived. Surprisingly, over 74% resembled S-type cells. In coculture experiments, S-type cells protected N-type cells from apoptosis induced by the oncogenic ALK inhibitor TAE684. Western blotting analyses showed that ALK, protein kinase A (AKT) and STAT3 signalling were stimulated in the cocultures. Furthermore, the conditioned medium from S-type cells activated these downstream signalling molecules in the N-type cells. The activation of STAT3 in the N-type cells was ALK-independent, while AKT was regulated by the ALK activation status. To identify the responsible soluble factors, we used a combination of transcriptomic and proteomic analysis and found that plasminogen activator inhibitor 1, secreted protein acidic and cysteine rich, periostin and galectin-1 were potential mediators of STAT3 signalling. The addition of recombinant proteins to the tumour cells treated with the ALK inhibitor partially enhanced cell viability. Overall, the tumour-derived S-type cells prevented apoptosis in the N-type cells via ALK-independent STAT3 activation triggered by secreted factors. The inhibition of these factors in combination with ALK inhibition could provide a new direction for targeted therapies to treat high-risk NB.

Keywords: ALK; STAT3; neuroblastoma; substrate-adherent cells; tumour microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anaplastic Lymphoma Kinase / antagonists & inhibitors
  • Anaplastic Lymphoma Kinase / genetics
  • Anaplastic Lymphoma Kinase / metabolism
  • Cell Adhesion*
  • Cell Proliferation
  • Cell Survival*
  • Coculture Techniques
  • Culture Media, Conditioned
  • Humans
  • Mass Spectrometry / methods
  • Mutation
  • Neuroblastoma / enzymology
  • Neuroblastoma / metabolism
  • Neuroblastoma / pathology*
  • Protein Kinase Inhibitors / pharmacology
  • Proteomics
  • Pyrimidines / pharmacology
  • STAT3 Transcription Factor / metabolism
  • Sequence Analysis, RNA / methods
  • Transcriptome

Substances

  • Culture Media, Conditioned
  • NVP-TAE684
  • Protein Kinase Inhibitors
  • Pyrimidines
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • ALK protein, human
  • Anaplastic Lymphoma Kinase

Associated data

  • GEO/GSE139235